T. Rowe closes capital appreciation fund

Baltimore Sun (MD) |

July 01--Baltimore-based investment firm T. Rowe Price closed one of its biggest mutual funds to new investors Monday, saying it is concerned about keeping pace with its rapid rate of growth.

The Capital Appreciation Fund, which invests about 60 percent in stocks and the rest in bonds and cash, jumped from $13.6 billion in 2012 to $19.1 billion in 2013, according to the firm's 2013 annual report. The fund, which has posted positive returns in every year but two since its 1986 start, had $20.4 billion in assets at the end of March.

"The market has experienced a significant rally over the past five years and the Capital Appreciation Fund's assets have risen considerably, due to both market appreciation and inflows," portfolio manager David Giroux said in a statement. "If flows were to continue at this pace, it could eventually strain our ability to invest efficiently and result in a less effective investment strategy."

T. Rowe limited similar portfolios available to institutional investors last October, spokeswoman Heather McDonold said. Those portfolios are also closed to new clients as of market close Monday, the firm said in its announcement.

T. Rowe's U.S. Capital Appreciation Strategy represented $32.3 billion of its $711.4 billion in assets under management at the end of March, according to a press release. The fund will continue to accept investments from existing shareholders, as well as direct rollovers from qualified retirement plans into new T. Rowe Price IRAs.



(c)2014 The Baltimore Sun

Visit The Baltimore Sun at www.baltimoresun.com

Distributed by MCT Information Services

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Symbol Name Price Change % Volume
SNYYF Sany Heavy Equip Intl Hld 0.29 0.00 0.00 0



Symbol Last Price Change % Change










Q BioMed CEO provides a Corporate Update

Denis Corin, CEO of Q BioMed Inc. ”Q“, a biomedical acceleration and development company, focused on licensing and acquiring undervalued biomedical assets in the healthcare sector, provides a corporate update. Mr. Corin discusses the company's recent acquisition of Metastron, a radiopharmaceutical for cancer bone pain. Q BioMed is dedicated to providing these target assets; strategic resources, developmental support, and expansion capital to ensure they meet their developmental potential, enabling them to provide products to patients in need?.

Emerging Growth

Margaux Resources Ltd.

Margaux Resources Ltd is a Calgary based resource company. The Company is focused on its Jersey Emeral Tungsten-Zinc property located in the southeast portion of British Columbia.